UNSPSC 51282308: Roxithromycin

This classification denotes a macrolide antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 21KOF230FA. European Medicines Agency schedules Roxithromycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10400MIG. Roxithromycin generally arises in the molecular formula C41H76N2O15.

The term ROXITHROMYCIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, no. 6, 1986, list 26.) ROXITHROMYCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule roxithromycin under HS 29415000 and SITC 54139. As of Q4 2014, ROXITHROMYCIN remains the US FDA Preferred Term for this commodity. Roxithromycin bears US NLM identifiers UMLS ID C0035891 and NCI Concept Code C818.

UNSPSC 51282308 Roxithromycin is a Commodity code that in practice captures state and local procurement of specialized pharmaceutical products and antimicrobial agents for public health and emergency response missions. Recent state and local opportunities under this code show procurement of antibiotics and opioid-reversal medications for direct distribution and inventory replenishment, often through piggyback or consortium purchasing agreements with established pharmaceutical vendors. The issuing bodies range from state departments of public health managing statewide medication stockpiles to county health systems acquiring naloxone and related medications for community health initiatives. Purchasing vehicles include both direct awards through cooperative purchasing consortiums (MMCAP Infuse) and competitive solicitations under formal invitation-for-bid processes.

Illinois Department of Public Health awarded a piggyback pharmaceutical contract through MMCAP Infuse to Chartwell Rx LLC on August 28, 2026 (solicitation 26482DPHPREPDB53392, IFB process, now closed) for $2,999,999.11 over three years covering antibiotic tablets in bulk packaging with staggered expiration profiles and quarterly replenishment cycles. Seminole County, Florida issued an IFB on June 30, 2026 (IFB60459723LAS, response deadline July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county community health building, fixed-fee pricing, and a two-year initial term with one-year renewal option. Recent activity concentrates in Florida and Illinois; the source does not support characterization of activity in other states or regions.